Ask AI
Latest evidence in obesity management

CE / CME

The Latest in Obesity Management: Current Evidence for Primary Care

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: September 25, 2025

Expiration: September 24, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Centers for Disease Control and Prevention. Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023. cdc.gov/nchs/products/databriefs/db508.htm. Accessed September 19, 2025.
  2. National Institute of Diabetes and Digestive and Kidney Diseases. Overweight & obesity statistics. niddk.nih.gov/health-information/health-statistics/overweight-obesity. Accessed September 19, 2025.
  3. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221-262.
  4. Swaleh R, McGuckin T, Myroniuk TW, et al. Using the Edmonton Obesity Staging System in the real world: a feasibility study based on cross-sectional data. CMAJ Open. 2021;9:E1141-E1148.
  5. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33:289-295.
  6. Obesity Medicine Association. Definition of obesity. obesitymedicine.org/blog/definition-of-obesity/. Accessed September 19, 2025.
  7. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2021; 9:419-426.
  8. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020;16:177-189.
  9. Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
  10. American Diabetes Association. The American Diabetes Association announces statement on liver disease in diabetes. diabetes.org/newsroom/press-releases/american-diabetes-association-announces-statement-liver-disease-diabetes. Accessed September 19, 2025.
  11. Semaglutide [prescribing information]. accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf. Accessed September 19, 2025.
  12. Tirzepatide [prescribing information]. accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf. Accessed September 19, 2025.
  13. Semaglutide [prescribing information]. accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf. Accessed September 19, 2025.
  14. Tirzepatide [prescribing information]. accessdata.fda.gov/drugsatfda_docs/label/2025/215866s031lbl.pdf. Accessed September 19, 2025.
  15. Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016;17:95-107.
  16. Cree-Green M, Triolo TM, Nadeau KJ. Etiology of insulin resistance in youth with type 2 diabetes. Curr Diab Rep. 2013;13:81-88.
  17. O’Hara V, Cuda S, Kharofa R, et al. Clinical review: guide to pharmacological management in pediatric obesity medicine. Obes Pillars. 2023:6:100066.
  18. Plutzky J, Ostrominski JW, Aroda VR, et al. Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial. Presented at: 2025 European Congress on Obesity; May 11-14, 2025. Abstract AD15.04.
  19. Ruseva A Bassan ME, Du E, et al. Reduction of the 10-year ASCVD risk in patients with overweight or obesity treated with semaglutide 2.4 mg in routine clinical care—a real-world study. Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Poster 1734-P.
  20. Guo L, Zhang H, Dai S, et al. Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight—a post hoc analysis of SURMOUNT-1, -3, and -CN. Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Poster 1729-P.
  21. Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873-1888.
  22. Heerspink H, Van Raalte D, Tuttle K, et al. Association of tirzepatide with kidney parameters in people with obesity and prediabetes from SURMOUNT-1 over 176 weeks. Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Abstract 103-OR.
  23. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30:2058-2066.
  24. Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025;31:278-285.
  25. Barzilay JI, Farag YMK, Durthaler J. Albuminuria: an underappreciated risk factor for cardiovascular disease. J Am Heart Assoc. 2024;13:e030131.
  26. Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691-702.
  27. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-2099.
  28. Newsome PN, Armstrong MH, Bakulin I, et al. Weight-independent benefits of semaglutide on histology and non-invasive tests in participants with biopsy-defined MASH: Post hoc analysis of the ESSENCE trial part 1. Presented at: 2025 European Congress on Obesity; May 11-14, 2025. Abstract AS4.
  29. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. 2024;391:299-310.
  30. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
  31. Bischoff M, Zimny S, Feiner S, et al. Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients. Eur J Nutr. 2022;61:2725-2735.
  32. Niu J, Al-Yaman W, Pinyopornpanish K, et al. The long-term effect of weight loss on the prevention of progression to cirrhosis among patients with obesity and MASH-related F3 liver fibrosis. Int J Environ Res Public Health. 2024;21:708.
  33. Machado MV. MASLD treatment-a shift in the paradigm is imminent. Front Med (Lausanne). 2023;10:1316284.
  34. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.
  35. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049-2057.
  36. Ard J, Lee C, Cao D, et al. Sustained weight reduction by thresholds in adults with obesity and prediabetes treated with tirzepatide over 176 weeks (SURMOUNT-1). Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Abstract 144-OR.
  37. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26-36.
  38. Horn D, Aronne L, Dunn J, et al. Time to reach weight reduction thresholds with tirzepatide vs. semaglutide—a post hoc analysis of SURMOUNT-5. Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Abstract 2202-LB.
  39. Ng CD, Divino V, Wang J, et al. Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes. Presented at: ENDO 2025; June 12-15, 2025. Abstract MON-716.
  40. le Roux C, Done N, Brnabic AJM, et al. A comparison of tirzepatide vs semaglutide for weight reduction over 6 months of treatment in adults with obesity in US clinical practice settings. Presented at: ENDO 2025; June 12-15, 2025. Abstract SAT-696.
  41. Wharton S, Freitas R, Hjelmesaeth J, et al. Efficacy and safety of semaglutide 7.2 mg in obesity—the STEP UP trial. Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Abstract 1966-LB.
  42. Garvey WT, Blüher M, Contreras CKO, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393:635-647.
  43. Dahl K, Adelborg K, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist—results of a phase 1b/2a clinical trial. Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Abstract 2002-LB.
  44. Wang JY, Kang JW, Wu CY, et al. The effects of incretin-based therapies on weight reduction and metabolic parameters in children with obesity: a systematic review and meta-analysis. Obes Rev. 2024;25:e13686.
  45. Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesity - a randomized trial. N Engl J Med. 2025;392:555-565.